Intranasal insulin improves cognition and modulates β-amyloid in early AD

Abstract

The results of this pilot study support further investigation of the benefits of intranasal insulin for patients with Alzheimer disease, and suggest that intranasal peptide administration may be a novel approach to the treatment of neurodegenerative disorders.